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Abstract 
Lonidami ne, 1-(2-4-dichlorobenzyl)-1-H-indazol-
3-carboxylic acid. is an anticancer drug that has its 
primary action on cellular metabolism rather than cell 
division. Since lonidamine is not effective in all tu-
mor cells, we have tested it in two human-tumor cell 
culture lines: MOL T-4, a T-leukemia and U-87 MG. a 
glioma. Lonidamine exposure of MOL T-4 cells at 
50 µg/mL and pH 6.7 disrupted the mitochondria 
within 1 h of treatment. The mitochondria were 
swollen and the cristae were disrupted. When the 
treated cells were re-incubated in fresh medium at 
pH 7.4 the mitochondria rapidly returned to their 
normal morphology. The U-87 MG glioma cells did 
not show ultrastructural disruption after 1-h treatment 
with lonidamine at concentrations up to 200 µg/mL 
at pH 6.7 
In the concentration range of 25 µg/mL to 
200 µg/mL. lonidamine did not produce any cell 
killing in MOL T-4 after a 1-h exposure at pH 7.4, 
although the drug had some limited effectiveness at 
pH 6.7. Compared to sham-treated controls, long 
exposures to 100 µg/mL of lonidamine at pH 6.7 
reduced survival in MOL T-4 to 92% and 53% after 
6-h and 24-h exposures, respectively. Survival of U-
87 MG glioma cells was also strongly pH dependent, 
a 2-h exposure to 50 µg/mL lonidamine at pH 7.4 
did not cause cell death; however, survival dropped to 
84% of the control at pH 6.65. 
Key words: lonidamine, ultrastructure, mitochondria, 
morphology, hyperthermia, cell killing, MOL T-4, glioma, 
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3-carboxylic acid, is a novel anticancer drug, which 
has been undergoing Phase I and Phase II clinical 
trials by itself (Band et al. 1984: Evans et al. 1984: 
Gulisano et al. 1987) and in conjunction with radio-
therapy (Cripps et al. 1988). It is reported to act by 
interfering with respiration in the mitochondria rather 
than as a mitotic poison, like most other anticancer 
drugs (Caputo and Silvestrini 1984). Lonidamine 
inhibits aerobic and anaerobic lactate production 
(Floridi et al. 1981a,b; De Martino et al. 1984), 
inhibits mitochondrially bound hexokinase (De Martino 
et al. 1984) and is reported to produce ultrastructural 
changes in the mitochondria and the plasma mem-
brane (Floridi et al. 1981a,b; De Martino et al. 1984: 
Arancia et al. 1988: Floridi et al. 1987). 
Since lonidamine acts on the cell's metabolism 
rather than cell division, it has the potential to cause 
tumor regression in new ways. In addition, since the 
treated cells are in a weakened state, synergism 
between lonidamine and ionizing radiation, 
hyperthermia. or other chemotherapeutic agents is 
possible (Kim et al. 1984: Starace et al. 1987: 
Bagnato et al. 1987; Floridi et al. 1987: Hahn et al. 
1984; Silvestrini et al. 1983: Kim et al. 1986). 
Although effects of lonidamine have been 
reported in a number of cell systems, it is not 
effective in all (De Martino et al. 1984). Thus, it is 
important to test various types of tumor cells to 
further understand the mode of action of lonidamine. 
Its effect on two human-tumor cell lines, MOL T-4 
and U-87 MG, are reported here. 
We have used transmission and scanning 
electron microscopes to observe the amount of 
structural damage in MOL T-4 and U-87 MG glioma 
cells immediately after lonidamine exposure and after a 
short incubation time. The level of cell killing 
induced by the drug has also been measured in order 
to correlate survival with morphological changes. It is 
important to observe morphological changes after 
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lonidamine exposure because it may become clinically 
useful in conjunction with other drugs, heat or radia-
tion. Thus identification of organelles, which are the 
targets of lonidamine, will offer clues to its mode of 
action and may suggest further combinations of 
treatments to expand its use. In addition, different 
cell types from different tissues may react differently 
to the drug. Therefore, it is important to build up a 
body of experience about the morphological and 
toxicological effects of lonidamine. 
The MOL T-4 cell line is derived from a T-cell 
leukemia and has many interesting properties: it is 
radiation-sensitive; it has a large number of pycnotic 
nuclei when it dies, similar to the characteristic 
apoptotic death seen in circulating lymphocytes; it 
does not repair sublethal damage; and it does not 
show synergistic cell killing by heat and radiation 
{Raaphorst et al. 1983; Szekely and Lobreau 1985). 
The apoptotic death of MOL T-4 cells allows cell 
killing to be measured by trypan blue dye exclusion or 
flow cytometry after radiation or drug treatment 
(Szekely et al. 1985). 
The gliobastoma cells, U-87 MG, are grade Ill 
human astrocytoma cells. The morphology and 
growth characteristics of glioma cell lines have been 
studied extensively ( Collins et al. 1979, 1980). Since 
human gliomas are difficult to treat and are often 
malignant (De Ridder et al. 1987), agents such as 
lonidamine, which may be useful on their own or with 
radiation or hyperthermia, may offer increased tumor 
cell killing. 
Materials And Methods 
Cell Culture 
The MOL T-4 cell line was established by 
Minowada et al. {1972). The cells resemble relatively 
mature T-lymphocytes; they form rosettes with 
unsensitized sheep red blood cells, and they carry 
surface antigens present in normal human T-cells and 
thymus leukemia {Minowada et al. 1972; Szekely 
et al. 19876). 
MOL T-4 cells were grown in RPMI 1640 
medium containing 10% heat-inactivated fetal bovine 
serum. They were maintained in suspension in loose-
ly capped T75 Falcon plastic flasks at 37°C in a 5% 
CO
2 
humidified atmosphere. They were maintained in 
log-phase growth by subculturing every 3 to 4 days 
and their doubling time ranged from 24 h to 32 h. 
5 
They were seeded at 10 cells /T75 flask and grew to 
approximately 2.5 x 10
6 
cells/T75 flask at the time of 
subculture. 
The U-87 MG glioma cells grow as a monolayer 
of epithelia-like cells in DME/F-12 medium with 15% 
heat-inactivated fetal bovine serum, and 10 mM 
NaHC0 3 and 20 mM HEP ES buffering in a 2% CO2 
humidified atmosphere. For glioma cells used in 
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microscopy, the medium was supplemented with gluta-
mine to 1.83 g/L, sodium pyruvate to 0.11 g/L and 
glucose to 4.5 g/L. Cells were seeded at 10
5 
cells/T75 flask and were subcultured weekly by 
trypsinization. For SEM and TEM the cells were 
grown to confluence at approximately 3 x 10 6 
cells /flask. 
Lonidamine Treatment 
For the MOL T-4 cells, T25 culture flasks 
containing 15 ml of medium were placed overnight in 
incubators containing a humidified CO
2 
atmosphere of 
N 25% for pH 6. 7 and 5% for pH 7.4 to equilibrate 
pH and temperature. The pH was measured with a 
Markson 5650 pH meter. The 5 x 10
6 
cells were 
pelleted from a stock culture and resuspended in the 
pH equilibrated medium. Lonidamine was added at 
the test concentration from a stock solution at 
10 mg/ml in dimethyl sulfoxide {DMSO). The 
DMSO was used to increase the solubility of 
lonidamine and decrease the amount of solvent added 
to the culture media. The flasks were then returned 
to their respective incubators. 
For the glioma cells, the pH was adjusted by 
adding HCI to the HEPES buffered medium before the 
flasks with cells were placed in an incubator 
containing a 2% CO2 humidified atmosphere. The pH 
remained constant during the treatment. 
Electron Microscopy 
For scanning electron microscopy {SEM), 
lonidamine-treated MOL T-4 cells were fixed by adding 
3 ml of sample to 9 ml of 4% glutaraldehyde in 
Hank's buffer with 0.04 mol/L sucrose. The fixation 
time was 30 min. The sample was then rinsed twice 
in Hank's buffer with 0.04 mol/L sucrose, and it was 
allowed to settle on poly-L-lysine-coated glass 
coverslips. Since the U-87 MG cells grow attached to 
a surface, they were grown and fixed on glass 
coverslips placed within the flasks. Both types of 
cells on the coverslips were dehydrated through a 
graded series of ethanol and then amyl acetate before 
being critically point-dried with CO2 • Cells were viewed 
in an ISi microscope operated at 15 kV. 
For transmission electron microscopy {TEM), the 
U-87 MG cells were scraped off the flask. The 
MOL T-4 or U-87 MG cells were pelleted from the 
medium, and then fixed and dehydrated in acetone by 
Hayat's {1972) rapid procedure, using Millonig's phos-
phate buffer before being embedded in Spurr's epoxy 
mixture. Gold sections were stained with 2% uranyl 
acetate and Reynold's lead citrate, and viewed in a 
Philips EM 300 electron microscope at 80 kV. 
Cell Survival 
MOL T-4 survival was measured by either flow 
cytometry, using a method developed for radiation and 
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glucocorticoid-induced killing, or by trypan blue dye 
exclusion (Szekely et al. 1985; 1987 a). Briefly, for 
try pan blue staining, one part of 1 % try pan blue in 
distilled water was added to five parts of cells in 
medium. After a 5 min equilibration period, the cells 
were scored under an optical microscope and cells 
that had taken up the stain were scored as dead 
cells. For flow cytometry a 4 ml sample of MOL T-4 
cells in medium was analysed in an Ortho 
Cytofluorograf 50 H interfaced with a 2150 Data 
General Micro Nova computer. The flow rate was 
approximately 200 cells/s. A 0.8 mW He-Ne laser 
was used as the light source. Axial light-loss and 
right-angle scatter were collected for analysis. The 
three-dimensional scattergram generated by plotting 
the axial light-loss versus the right-angle scatter was 
used to determine the percentage of live and dead 
cells. Survival was measured at various times 
following the lonidamine exposure. Immediately 
following the treatment, the MOL T-4 cells were 
resuspended in fresh medium and kept at pH 7.4 until 
survival was measured. 
The glioma cells were plated in dishes 
immediately following the drug exposure. Survival 
was determined by counting the number of colonies 
produced by the treated cells, as previously described 
(Raaphorst and Azzam 1981). Briefly, cells were 
trypsinized after treatment, resuspended in fresh 
medium counted and plated at a concentration chosen 
to give approximately 10 to 150 colonies per dish. 
Colonies were counted at 12 to 14 days after plating. 
The plating efficiency averaged 27% for the series of 
experiments. Untreated controls were plated after ex-
posure to media or media plus DMSO at the concen-
tration used in the treatment series. No difference 
was seen. 
~ 
MOL T-4 T-lymphocytes were exposed to 
lonidamine for 1 h at pH 7.4 and pH 6. 7 followed by 
a 24-h incubation in fresh medium at pH 7.4. Since 
survival measured by trypan blue staining or flow 
cytometry gave similar results, the experiments using 
both methods were pooled. 
Table 1 gives the relative survival levels of 
MOL T-4 cells after 1-h exposure to various 
concentrations of lonidamine. Measurements of survival 
immediately after the exposure (not shown) showed 
no decrease in survival at either pH or lonidamine 
concentration tested. High drug concentrations, up to 
200 µg/ml, did not cause very much cell death at 
24 h after the exposure. At 200 µg/ml. cell survival 
averaged 90% in cells treated at pH 6.7. The 
exposures were carried out at low pH because work 
by Kim et al. (1984) has shown that in some cell 
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TABLE 1. MOL T-4 survival 24 h after a 1-h 
lonidamine exposure 
Number of 
Treatment % Survival* experiments 
Control pH 7.4 100 7 
Control pH 6.7 99 ± 0.3 7 
5 µg/mL pH 6.7 95 1 
25 µg/ml pH 6.7 93 1 
50 µg/ml pH 6.7 97 ± 2.2 7 
100 µg/mL pH 6.7 85 ± 13.9 7 
200 µg/mL pH 6.7 90 ± 2.0 6 
* Normalized to pH 7.4 control 
systems lonidamine is much more effective in cell 
killing at low pH. 
In clinical practice, serum concentrations of 
10 µg/mL to 40 µg/ml are found during treatments 
that last for several days. Since a 1-h exposure did 
not produce much cell death, longer exposure times 
were tried. Although longer exposures produced more 
cell killing, (Tables 2 and 3), there still was a high 
survival rate. A 24-h exposure at 100 µg/ml gave 
approximately 50% survival and the percentage of 
survivors increased to an average of 77% by 24-h 
posttreatment. 
Although a large concentration of lonidamine and 
a long exposure time is required to decrease survival 
in MOL T-4 cells. samples viewed in the transmission 
electron microscope show morphological damage at 
doses that do not cause significant cell killing. The 
cells exposed to 50 µg/ml (Fig. 1) and 200 µg/ml 
(Fig. 2) for 1 h show disrupted mitochondria. The 
swollen mitochondria are near the cell surface and, in 
some cases, they break through the surface. The 
treated cells have debris on their surface ( arrows in 
Figs. 1 and 2). The cell surface also has a swollen 
appearance with fewer surface ruffles and more 
microvilli than the controls. Fig. 3 shows an 
untreated cell after 1 h in medium at pH 6. 7. The 
mitochondria are well formed with visible cristae. 
The surface is not as smooth as in the treated cells. 
When the MOL T-4 cells are treated at pH 7.4 
(Fig. 4) there is some slight swelling of the mitochon-
dria (arrow), but most are similar to those seen in 
the controls. 
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TABLE 2. MOL T-4 survival after a 6-h lonidamine exposure 
No posttreatment incubation 24-h incubation 
Treatment % Survival* Number of % Survival Number of 
experiments experiments 
pH 6.7 Control 99 ± 0.6 6 99 ± 1.1 6 
50 µg/mL 98 ± 1.0 6 83 ± 9.6 6 
100 µg/mL 92 ± 3.6 6 72 ± 8.5 6 
150 µg/mL 77 ± 8.1 6 47 ± 12.4 6 
pH 7.4 Control 100 6 100 6 
50 µg/mL 100 ± 0.3 3 100 3 
100 µg/mL 99 ± 0.9 3 99 ± 0.6 3 
150 µg/mL 96 ± 2.3 3 89 ± 3.2 3 
* Normalized to pH 7.4 control 
TABLE 3. MOL T-4 survival after a 24-h lonidamine exposure 
No posttreatment incubation 24-h incubation 
Number of Number of 
Treatment % Survival* experiments % Survival experiments 
pH 6.7 Control 93 ± 7.0 4 100 2 
25 µg/mL 89 ± 8.7 4 96 2 
50 µg/mL 73 ± 10.3 4 78 2 
100 µg/mL 53 ± 19.7 4 77 2 
pH 7.4 Control 100 1 100 2 
25 µg/mL 98 1 100 2 
50 µg/mL 99 1 100 1 
100 µg/mL 100 1 93 1 
* Normalized to pH 7.4 control 
684 
Morphological effects of lonidamine 
Fig. 1. A transmission electron micrograph of MOLT-
4 cells exposed to 50 µg/mL lonidamine for 1 h at 
pH 6.7. Swollen mitochondria are shown by arrows. 
Fig. 2. A transmission electron micrograph of a 
MOL T-4 cell exposed to 200 µg/mL lonidamine for 
1 h at pH 6. 7. Swollen mitochondria are shown by 
arrows. 
The cell surface can be effectively observed with 
the scanning electron microscope. Figs. Sa and Sb 
are control MOL T-4 cells, which were incubated in 
medium at pH 7.4 and pH 6.7, respectively. MOL T-4 
cells are generally spherical with broad ridges over 
their surface. Some cells, however, show a uropod 
structure as described by Bessis (1977) along with 
multiple ruffles and small filaments. Cells incubated 
for 1 h at pH 6. 7 have more surface projections and 
ruffles than the pH 7.4 control. After a 1-h exposure 
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Fig. 3. A control MOL T-4 cell sham-treated with 
medium at pH 6.7 
Fig. 4. A MOL T-4 cell exposed to 50 µg/mL 
lonidamine for 1 h at pH 7.4. The mitochondria 
(arrow) are slightly swollen, but the cristae remain 
well formed. These mitochondria may be compared 
to those shown in Fig. 1. There the cells were given 
the same treatment except the pH was 6. 7. 
to 50 µg/mL lonidamine at pH 6.7 (Fig. 6), the cell 
surface still looks similar to the pH 6. 7 control. In 
general, the SEM views of treated and pH 6.7 control 
cells were similar. Only the 200 µg/mL lonidamine-
treated sample had extracellular debris and disrupted 
microvilli on the surface. 
When cells that have been exposed to 
lonidamine are incubated at pH 7.4 in fresh medium 
Joseph G. Szekely, Anya U. Lobreau, G. Peter Raaphorst, et al. 
Fig. 5. Scanning electron micrographs of control cells 
sham-treated with medium at (a) pH 7.4 and (b) 
pH 6.7. 
for 1 h, the cell surface regains the appearance of 
pH 7.4 control cells with the exception of some long 
projections. The 200 µg/mL lonidamine-treated 
sample (Fig. 7) also shows some remaining cellular 
debris (arrow). In the TEM, the return to a normal 
morphology is seen more easily. After a 1-h incuba-
tion at pH 7.4, the mitochondrial swelling has 
decreased dramatically and the cristae have reformed 
to a great extent. The 50 µg/mL lonidamine-treated 
sample (Fig. 8) looks very similar to the control and 
the 200 µg/mL-treated sample (Fig. 9) has only a few 
swollen mitochondria. The numbers of long, thin 
projections seen in the SEM, are visible in the TEM 
sections (Figs. 8 and 9) along with some extracellular 
debris. 
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Fig. 6. A MOL T-4 cell exposed to 50 µg/mL 
lonidamine for 1 h at pH 6.7. 
Fig. 7. A MOL T-4 cell exposed to 200 µg/ m L 
lonidamine for 1 h at pH 6.7, followed by 1-h 
incubation in fresh medium at pH 7.4. 
Glioma cells, U-87 MG, have also been tested 
for lonidamine toxicity. Since they grow as attached 
cells, the more stringent method of colony counting 
was used. A summary of U-87 MG survival is 
shown in Table 4. The values are normalized to the 
plating efficiency of control cells exposed at pH 7.4. 
After a 1-h exposure to 50 µg/mL at pH 6.65, the 
relative survival fell to 91 % of the control and 
decreased to 84% after a 2-h exposure. As with 
MOL T-4 cells, there is a strong pH dependence of the 
lonidamine-induced killing. Long exposures of 8 h at 
Morphological effects of lonidamine 
Fig. 8. A transmission electron micrograph of a 
MOL T-4 cell exposed to 50 µg/mL lonidamine for 1 h 
at pH 6.7, followed by a 1-h incubation in fresh 
medium at pH 7.4. 
Fig. 9. A MOL T-4 cell exposed to 200 µg/mL 
lonidamine at pH 6.7 followed by a 1-h incubation in 
fresh medium at pH 7.4. 
lower concentrations of lonidamine also did not de-
crease survival greatly. Thus, U-87 MG glioma cells 
are not very sensitive to lonidamine under these 
conditions. 
At the ultrastructural level the glioma cells are 
less reactive to the drug than are MOL T-4. The 
glioma cells are large with many vacuoles, residual 
bodies and lysosomes. The mitochondria are small 
and not well defined in the micrographs (Fig. 10). 
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TABLE 4. Survival of U-87 MG glioma cells after 
a lonidamine exposure 
pH Concentration Time Survival* 
(µg/mL) (h) % 
7.4 50 1 100 
7.4 50 2 100 
7.4 50 8 86 :t 8.6 
7.4 10 1 100 
7.4 10 2 100 
7.4 10 8 84 :t 5.6 
7.2 50 2 97 :t 3.1 
7.0 50 1 95 :t 2.1 
7.0 50 2 84 :t 5.1 
6.65 50 1 91 :t 3.6 
6.65 50 2 84 :t 8.7 
*Normalized to pH 7.4 control 
Fig. 10. A transmission electron micrograph of a 
control U-87 MG glioma cell sham-treated with 
medium at pH 6. 7 for 1 h. 
After a 1-h exposure to concentrations of up to 
50 µg/mL lonidamine at pH 6.7, there was no visible 
difference between treated and control cells. After an 
1-h exposure to 200 µg/mL lonidamine at pH 6.6, the 
endoplasmic reticulum and mitochondria were swollen 
(Fig. 11), but they returned to their usual morphology 
after a 1-h incubation in fresh medium at pH 7.4 
(Fig. 12). 
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1.0~m • 
Fig. 11. A U-87 MG g!ioma cell exposed to 
200 µg/mL lonidamine at pH 6.7 for 1 h. 
Fig. 12. A U-87 MG glioma cell exposed to 
200 µg/mL lonidamine at pH 6.7 for 1 h followed by 
a 1-h incubation at pH 7.4 in fresh medium. 
In the scanning electron microscope views, there 
were no visible differences noted between the control 
cells and those treated at pH 7.4 or pH 6.7 (Figs. 13 
a-d). The glioma cells were flat, thin cells, with 
many microvilli on their surface. Thus, by morpho-
logical assessment the glioma cells were little affected 
by lonidamine. This correlated with the small effect 
of the drug on survival. 
Discussion 
Although lonidamine is being tested as an 
anticancer agent in humans. it is not equally effective 
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in all in vitro test systems (De Martino et al. 1984). 
In human and murine lymphocytes, lonidamine is 
reported to be more effective in B and null leukemia 
than in T-cell leukemia (Natali et al. 1984; Floridi 
et al. 1981b). The MOL T-4 cells were selected as a 
test system for lonidamine because they are a leuke-
mia that carries a number of T-cell markers. including 
surface markers for sheep red blood cell rosetting. 
They die by apoptotic death similar to normal 
lymphocytes and they are radiation sensitive, which 
makes them of interest for studies involving synergism 
between radiation, heat or lonidamine (Minowada 
et al. 1972; Szekely et al. 1987a; Raaphorst et al. 
1983). 
Since it had been reported that brain cells are 
not affected by lonidamine (De Martino et al. 1984) 
and, since brain tumors are difficult to treat, we also 
looked at the effects of lonidamine on a malignant 
glioma cell line U-87 MG. These cells grow attached 
to the flask with an epithelial-like morphology. in con-
trast to the free-floating MOL T-4 cells. Glioma cells 
are relatively radioresistant; hence, it is of interest to 
compare their response to lonidamine with that of the 
radiosensitive MOL T-4 cells. 
The survival results showed many MOL T-4 and 
U-87 MG cells surviving the lonidamine treatment 
even when the dose was large compared to the plas-
ma level achievable in humans (Hahn et al. 1984). 
Although the MOL T-4 and U-87 MG cells were 
relatively insensitive to lonidamine, they both showed 
a strong pH dependence of cell death and morphologi-
cal change. This increased cell death at low pH 
agrees with reports on other cell types ( Kim et al. 
1984; Stryker and Gerweck, 1988). This fact is espe-
cia I ly important since one of the suspected 
mechanisms of hypothermic killing in tumors is due to 
the lower pH level within the center of the tumor. 
Combined lonidamine and hyperthermia treatments are 
being tried and these results suggest a synergism is 
possible. For both MOL T-4 and glioma cells there 
was no significant cell killing at pH 7.4 even after 
6 h of exposure to the drug. 
In the electron micrographs it was clear that in 
MOL T-4 ultrastructural damage of the mitochondria 
took place within a 1-h exposure to lonidamine at 
pH 6. 7. There was also some slight damage at 
pH 7.4. The mitochondria, however, regained a 
structure very close to the control within 1 h after 
the cells were returned to normal medium at pH 7.4. 
Therefore, the relative resistance of MOL T-4 to 
lonidamine, as compared to lymphocytes or Ehrlich tu-
mor cells ( Natali et al. 1984; Arancia et a I. 1988; 
Floridi et al. 1981b). may be explained by the MOLT-
4 cells rapid return to a normal ultrastructure after 
removal of the drug. The rapid return of the ultra-
structure to a normal appearance suggests that 
lonidamine should be present at its maximum concen-
Morphological effects of lonidamine 
(a) 
{b) (d) 
Fig. 13. Scanning electron micrographs of U-87 MG cells treated for 1 h. (a) Control cell 
sham-treated at pH 7.4, (b) control cell sham-treated at pH 6.7, (c) 50 µg/ml lonidamine-treated 
cell exposed at pH 6.7 and (d) 200 µg/mL lonidamine-treated cell exposed at pH 6.7. 
tration to be of use clinically, either alone or as part 
of a combination treatment. 
U-87 MG glioma cells, on the other hand, are 
not greatly altered by the lonidamine exposure. Al-
though some mitochondria swelling was seen at the 
highest lonidamine concentration used, there was little 
difference between control and treated samples in both 
the SEM and TEM observations. The ultrastructural 
appearance of cultured glioma cells has been described 
earlier (Collins et al. 1979; 1980) and in our hands 
the U-87 MG cells had an ultrastructure similar to 
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that already reported. The only additional factor was 
the large number of residual bodies we observed in 
our culture conditions. Since the glioma cells were not 
greatly altered by lonidamine in the concentrations we 
used, it is possible that the reduced transport of 
lonidamine across the plasma membrane is a factor, 
or that the activation state of the mitochondria was 
such that they were not affected by the drug. It has 
been reported that mitochondria in the condensed 
state (111) are disrupted by lonidamine (De Martino et 
al. 1984). From our observations, the U-87 MG cells 
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and MOL T-4 cells do not show the condensed 
structure characteristic of mitochondria, which are ac-
tively producing energy. In our control micrographs 
at pH 6.7 or pH 7.4, the mitochondria have an 
expanded morphology with visible finger-like cristae. 
Although lonidamine does not dramatically reduce 
viability in all cell types, such as the MOL T-4 or U-
87 MG, the oxidative stress produced by the drug 
during and shortly after the exposure suggests that 
lonidamine may be a useful treatment in conjunction 
with X-irradiation, hyperthermia or chemotherapy with 
other drugs. Thus, even if tumor cells do not 
respond to lonidamine directly, they may show syner-
gistic killing in combined treatments. In fact, glioma 
cells have shown enhanced cell killing during combined 
lonidamine-hyperthermia treatment ( data to be 
published elsewhere). Although the ultrastructure of 
the nucleus was not altered by lonidamine, there are 
reports that it inhibits the repair of sublethal damage 
in some cell types (Kim et al. 1986; Hahn et al. 
1984), but not in all (Danjoux et al. 1988). 
The fact that lonidamine is more active at low 
pH also suggests that it will be valuable in combina-
tion with heat or irradiation. Solid tumors frequently 
have a hypoxic core, which is at a lower pH than the 
rest of the tumor. The rapid growth of tumor cells 
also makes the center of solid tumors more acidic. 
Thus, the likelihood that lonidamine will interact syn-
ergistica II y with hyperthermia or irradiation is 
increased. 
In our observations of MOL T-4 and U-87 MG 
we have not seen any large blebs or blistering of the 
plasma membrane as reported by De Martino et al. 
(1984). Lonidamine does have an effect on molecular 
transport across the outer mitochondrial membrane, 
however, as reflected by its ability to increase the re-
sponse of tumor cells to adriamycin (Floridi et al. 
1987; Starace et al. 1987; Bagnato et al. 1987). 
Differential effects of lonidamine have also been shown 
by the freeze fracture technique (Aranda et al. 1988). 
They report a dose-dependent clustering of 
intramembrane particles in lymphocytes and leukemic 
cells. 
Conclusion 
We have shown the effect of lonidamine expo-
sure to cells of two types: human T-leukemia and 
glioblastoma. Survival of both cell lines was relatively 
insensitive to the drug at low pH and had no signifi-
cant response at pH 7.4. MOL T-4, a T-leukemia 
line, had major ultrastructural damage in the mito-
chondria after a 1-h exposure; however the mitochon-
dria rapidly regained their ultrastructural appearance 
after a 1-h incubation in fresh medium at pH 7 .4. 
U-87 MG glioma cells did not show significant 
ultrastructural damage after the lonidamine exposures. 
690 
This reinforces the idea that various cell types show 
a range of response to the drug and that lonidamine 
efficiency in cancer treatment may be site dependent. 
These data indicate the necessity of evaluating 
lonidamine responses for all types of tumors targeted 
for clinical trials of lonidamine therapy. 
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Discussion With Reviewers 
U.T. Brunk: Would you please expand on the type 
of oxidative stress you suggest is produced by the 
drugs? Are formation of oxygen-derived free radicals 
involved? 
Authors: We concur with the widely held view that 
lonidamine acts primarily in the condensed mitochon-
dria as an inhibitor of the aerobic glycolytic pathway. 
In cancer cells there is an increased glycolytic flux 
due to their higher energy requirements. It is 
suggested by many workers that lonidamine inhibits 
aerobic lactate production by inhibiting the action of 
mitochondrially bound hexokinase, which is present in 
the outer mitochondria membrane of neoplastic cells. 
Floridi and Lehninger (1983) also suggest that 
lonidamine inhibits electron transport in the NAO-
linked dehydrogenase system. The drug produces an 
inhibition of oxygen uptake by cultured cells, which 
increases dramatically at low pH (Stryker and Gerweck 
1988). In conjunction with hyperthermia, lonidamine 
may act synergistically because condensed mitochon-
dria are produced from the imbalance in energy 
requirements and the reduced oxygen supply induced 
by the heat treatment. Evidence suggests that 
lonidamine acts by biochemical disruption of oxygen 
utilization and energy production, and not by a free 
radical mechanism. 
Joseph G. Szekely, Anya U. Lobreau, G. Peter Raaphorst, et al. 
H. Gamliel: For the various modes of analysis, U-87 
MG cells were grown in flasks, and/or glass 
coverslips, and/or in dishes. Can you provide data to 
support your assumption that they grow the same on 
all these kinds of substrates? Why did you not use 
the widely acceptable, special type of Petri dish with 
an inner lining that can serve for SEM, TEM, LM, 
etc.? Why did you not embed cells while attached to 
the substrate? 
Authors: The flasks and dishes are made from the 
same material and have the same surface treatment. 
Large numbers of dishes are required for the survival 
experiments and hence, specialized dishes would not 
be practical for that use. Flasks are the most conve-
nient vehicle for long-term culture of the cell stocks. 
In retrospect, the inner linings you suggest would 
have been ideal for the microscopy part of the 
experiment; however, we did not consider them at the 
time. We are satisfied that, since control and treated 
cells are being compared, any effect of the glass sub-
strate (if one exists) would be common to both 
samples. 
H.Gamliel: Long exposure to lonidamine seems to be 
not less important than concentration. Thus, it is 
not clear why no data is provided on the exposure of 
U-87 MG for 24 h, the most useful time to test, as 
indicated with MOL T-4. 
Authors: One purpose of the experiments was to 
compare the survival and morphology of MOL T-4 and 
U87-MG after lonidamine exposure with results 
published with other cell lines. The shorter drug ex-
posure times of 1 h to 8 h were chosen to corre-
spond with experiments published by other workers on 
other cell culture systems (see text reference list). 
Since in vivo exposures are much longer than this, we 
decided to extend some MOL T-4 experiments to 24 h. 
H. Gamliel: Why is it so important to show sensitiv-
ity at pH 6. 7? - although briefly discussed, it is not 
clear how in practice such a low pH can be achieved 
in-vivo (beside the point that the "center of solid 
tumors is more acidic")? Why "the likelihood that 
lonidamine will interact synergistically with 
hyperthermia or irradiation is increased"? Is there 
evidence that hyperthermia or radiation increases the 
acidity of tumor cells? 
Authors: Tumor growth relies on the supply of 
nutrients and drainage of waste by a functional vascu-
lar network. The generally higher level of metabolism 
in the oxygenated portion of the tumor and cell death 
in the center of a solid tumor produces an acidic en-
vironment. Heat or radiation causes vascular damage 
in tumors, which may lead to a nutritionally deprived, 
waste-product-rich and hence acidic environment. For 
example, Rhee et al. (1984) showed that the intrinsi-
cally acidic intratumor environment became further 
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acidic for 12 h after heating. Fellenz and Gerweck 
(1988) have shown that intracellular pH depends on 
extracellular pH and that thermal sensitivity is closely 
related to internal pH. Since the vasculature in 
normal tissues is usually resistant to heat relative to 
the vasculature in tumors (Song et al. 1980), a syner-
gistic effect between lonidamine and heat is expected. 
H. Gamliel: MOL T-4 cells, under our hands displayed 
villous surfaces, as did many other lymphoid leukemia 
cell lines. The SEM pictures provided show cells 
which could be categorized as suffering from air dry-
ing (displaying only ridges and undulating surfaces). 
Why did you have to add sucrose to your fixation 
solution? If osmolarity is the issue, it is now well 
established that the osmolarity of the vehicle (Hank's 
buffer) is more important than the total osmolarity of 
the fixative solution. Fixation with glutaraldehyde 
alone is not sufficient, and osmium tetroxide should 
be used also to prevent massive shrinkage of 
specimens and other artifacts of CPD. Did you 
compare your results with other methods using better 
fixation procedures, e.g., TAO, GTGO, etc.? 
Authors: We have tried various buffer-glutaraldehyde 
combinations and have found that the 4% 
glutaraldehyde in Hank's balanced salt solution plus 
0.04 mol/L sucrose suggested by Abugaber et al. 
(1981) gave good preservation of MOL T-4 cells. As 
they and you point out, buffer osmolarity is more im-
portant than that of the fixative, since the cell mem-
brane is not very osmotically active to glutaraldehyde. 
In our hands, the buffer and buffer plus 
glutaraldehyde fixative had osmolarities of 340 mosm 
and 775 mosm, respectively. We used this combina-
tion as our basic fixative and did not try any other. 
M. Albertsson: Are there any measurements available 
on how lonidamine penetrates into the hypoxic 
tumor's core when administered orally or 
intravenously? What about penetration in the brain 
tumor? 
Authors: We are not aware of any human data on 
the distribution of lonidamine within tumors. One of 
us (G.P.R.) is collecting biopsy material from patients 
treated with lonidamine to monitor its concentration in 
various organs and tumors. In rats lower 
concentrations with respect to the plasma are 
observed in most organs. Only kidney and liver 
concentrations approach the plasma value. The con-
centration of lonidamine in the brain is generally low. 
Additional References 
Abugaber AA, Lalague ED, Roy A, 
Champagne MR, Cousineau GH. (1981). The use of 
various buffers in the preparation of human 
Morphological effects of lonidamine 
lmphocytes for SEM observation. J. Microsc. 122, 
59-64. 
Fellenz MP. Gerweck LE. (1988). Influence of 
extracellular pH on cell energy status: Relationship to 
hyperthermic sensitivity. Radiat. Res. 116, 305-312. 
Floridi A. Lehninger AL. (1983). Action of the 
antitumor and antispermatogenic agent lonidamine on 
electron transport in Ehrlich ascites tumor mitochon-
dria. Arch. Biochem. Biophys. 226, 73-83. 
693 
Rhee JG, Song CW. Levitt SH. (1984). 
Thermosensitizing effect of heat-induced vascular 
damage. In: Hyperthermic Oncology. 1984. 
J. Overgaard (Ed.). Taylor and Francis, London and 
Philadelphia, pp. 153-156. 
Song CW. Kang MS. Rhee JG, Levitt SH. 
(1980). The effect of hyperthermia on vascular 
function, pH, and cell survival. Radiology, 137, 
795-803. 
